Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
British Journal of Haematology
|
July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.
Haematologica
|
December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.
Leukemia Research
|
May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC
Hyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.
Leukemia Research
|
May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
Marie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Philippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, et al.
Leukemia
|
August 1, 2025
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools
Sylvain Moinard, Benjamin Lebecque, Tom Lachaise, et al.
The Lancet. Haematology
|
December 22, 2015
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
Franck E Nicolini, Gabriel Etienne, Viviane Dubruille, et al.
Oncogene
|
June 24, 2020
Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms
Mira El-Khoury, Xénia Cabagnols, Matthieu Mosca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Jane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
British Journal of Haematology
|
July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
Philippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
British Journal of Haematology
|
July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.
Haematologica
|
December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.
Leukemia Research
|
May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC
Hyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.
Leukemia Research
|
May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
Marie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
Philippe Rousselot, Aude Charbonnier, Pascale Cony-Makhoul, et al.
Leukemia
|
August 1, 2025
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools
Sylvain Moinard, Benjamin Lebecque, Tom Lachaise, et al.
The Lancet. Haematology
|
December 22, 2015
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
Franck E Nicolini, Gabriel Etienne, Viviane Dubruille, et al.
Oncogene
|
June 24, 2020
Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms
Mira El-Khoury, Xénia Cabagnols, Matthieu Mosca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
Jane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.
British Journal of Haematology
|
July 1, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
Philippe Rousselot, Luigina Mollica, Joëlle Guilhot, et al.
Page
of 7